Alira Health

Alira Health

Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges

Since 1986, when the US Food and Drug Administration approved the first mouse monoclonal antibody (MAb) for clinical use, the global market for MAbs has expanded dramatically.

The success of this drug class has stimulated research into novel protein engineering methods, from which has come new bispecific antibodies (bsAbs), divided in IgG-like bsAbs and non–IgG-like bsAbs based on their structure.

Our experts conducted a deep evaluation of IgG-like bsAbs. The evaluation included general advantages and disadvantages compared with MAbs; described different formats and structural characteristics; and outlined how IgG-like bsAbs are applied in medical research as well as manufacturing considerations.

Access the article series “Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges” published by BioProcess International:

Experts behind the articles:
  • Jennifer Bratt
  • Angela Linderholm
  • Bryan Monroe
  • Steven M. Chamow

Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and bsAbs products can make a significant difference in your development journey.

Scientific Articles
Category:
Published on:
November 20, 2023

Related news

Scientific Articles November 20, 2023
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
CMC
Scientific Articles November 20, 2023
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)
CMC
Scientific Articles November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Webinars October 18, 2023
The Process of CDMO Selection for Antibody Development: Matching Capabilities to Need
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
CDMO CMC
Events September 27, 2023
Advances in Biologics and CGT
We are excited to share that we will be joining the Networking Reception: Advances in Biologics and CGT hosted by Catalent.
Biologics CMC
Scientific Articles September 21, 2023
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
CDMO CMC
Scientific Articles September 20, 2023
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
CMC Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.